Anticoagulant News and Research

RSS

Regado Biosciences employs over-allotment option to purchase additional shares of common stock

Regado Biosciences, Inc., today announced the exercise of the over-allotment option granted to the underwriters to purchase 921,500 additional shares of common stock, at a public offering price of $4.00 per share, in connection with its previously announced initial public offering of 10,750,000 shares of common stock, bringing the total gross proceeds from the offering to $46,686,000, before deducting the underwriting discounts and commissions and other offering expenses payable by Regado Biosciences.

7 Sep 2013

Hokusai-VTE findings provide fresh insight into patients with pulmonary embolism

In the treatment of venous thromboembolism (VTE), the oral anticoagulant edoxaban resulted in equal efficacy and better safety compared to standard warfarin when either drug was used with initial low molecular weight heparin (LMWH), according to the results of the Hokusai-VTE trial.

5 Sep 2013

NPS MedicineWise reiterates safety messages around newer oral anticoagulants

NPS MedicineWise is reiterating safety messages around the newer anticoagulants dabigatran (Pradaxa) and apixaban (Eliquis) following their PBS listing for preventing stroke on 1 September 2013 – and again for rivaxabaran (Xarelto) which was PBS listed in August for the same purpose.

2 Sep 2013

Mass screening programme of 75-76 year olds to identify undiagnosed AF

Stroke is the second cause of death worldwide. Atrial fibrillation is the most common clinically relevant cardiac arrhythmia in Europe, affecting approximately 1.5-2% of the general population.1 Prevalence is estimated to double in the next 50 years as the population ages.

2 Sep 2013

Use of anticoagulant does not reduce ischemic events among patients undergoing PCI

Use of the novel anticoagulant otamixaban did not reduce ischemic events compared with unfractionated heparin plus eptifibatide but increased bleeding among patients with non-ST-segment elevation acute coronary syndromes undergoing a percutaneous coronary intervention (PCI; procedures such as balloon angioplasty or stent placement used to open narrowed coronary arteries), according to a study published by JAMA.

2 Sep 2013

Research: General practitioners undertreat women with atrial fibrillation

General practitioners (GPs) undertreat women with atrial fibrillation (AF), according to research presented at ESC Congress 2013 today by Dr Pierre Sabouret from France. The analysis of more than 15,000 patients showed that women were undertreated with antithrombotic medications compared to men regardless of their stroke risk and comorbidities.

2 Sep 2013

Personalised management: The only way to close mortality gap for AF patients

Personalised management is the only way to close the mortality gap for patients with atrial fibrillation, according to an ESC consensus paper presented at ESC Congress 2013 by Professor Paulus Kirchhof (UK).

27 Aug 2013

Vanderbilt adds genetic screening for drug tacrolimus to PREDICT program

Vanderbilt has added genetic screening for the drug tacrolimus to its personalize medicine pharmacogenomics program PREDICT. The new drug screening protocol was added following data that shows a single genetic variation largely impacts different dose requirements for patients.

27 Aug 2013

Scientists grow cells that line blood vessels from human iPSCs

In a scientific first, Harvard Stem Cell Institute scientists have successfully grown the cells that line the blood vessels-called vascular endothelial cells-from human induced pluripotent stem cells (iPSCs), revealing new details about how these cells function.

23 Aug 2013

Boehringer signs agreement with Brigham to conduct long-term study program on oral anticoagulants

Boehringer Ingelheim, a research-based, global pharmaceutical company, today announced a multi-year agreement with Brigham and Women's Hospital, an internationally recognized teaching affiliate of Harvard Medical School known for its excellence in patient care, medical research and training of outstanding young health professionals.

17 Aug 2013

FDA grants Orphan Drug Designation to Alnylam ALN-AT3 for treatment of hemophilia B

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that the U.S. Food & Drug Administration (FDA) has granted an Orphan Drug Designation to ALN-AT3 as a therapeutic for the treatment of hemophilia B.

17 Aug 2013

"Risk calculator" enables doctors to estimate risk of venous thrombosis

In Austria, around 15,000 people a year develop a venous thrombosis, the occlusion of a vein that can result in a pulmonary embolism. A clot breaks free from a vein and travels via the bloodstream to the lungs, where it blocks vessels.

14 Aug 2013

AliveCor Heart Monitor for iPhone can detect heart rhythm problems, prevent strokes

A special iPhone case and app can be used to quickly and cheaply detect heart rhythm problems and prevent strokes, according to University of Sydney research presented at the Australia and New Zealand Cardiac Society conference today on the Gold Coast.

9 Aug 2013

Prothrombin complex concentrates more effective at reversing hemorrhage caused by warfarin

Prothrombin complex concentrates are faster and more effective than fresh frozen plasma at reversing hemorrhage caused by the anti-coagulant warfarin, despite plasma being the most commonly used therapy.

3 Aug 2013

August edition of NPS RADAR includes reviews for new medicines listed on PBS

The 10th anniversary edition of NPS RADAR contains reviews for new medicines listed on the Pharmaceutical Benefits Scheme including rivaroxaban (Xarelto), rotigotine patches (Neupro) and mifepristone (Mifepristone Linepharma) followed by misoprostol (GyMiso).

1 Aug 2013

Viewpoints: GOP's shutdown vow; Peter Orszag defends rationale behind Medicare payment board

A dozen Republicans in the Senate have said they'd rather shut down the government than provide funding for the Patient Protection and Affordable Care Act, the 2010 healthcare reform law better known as Obamacare. Meanwhile, more than 60 Republicans in the House have called on their leadership to cut off all federal support for the law in the coming fiscal year. And they complain when President Obama doesn't hold up his end of the bargain? (7/30).

1 Aug 2013

NPS MedicineWise finds little or no clinical benefit in switching to rivaroxaban for stroke prevention

With oral anticoagulant rivaroxaban set to be subsidised under the Pharmaceutical Benefits Scheme (PBS) for preventing stroke, NPS MedicineWise is urging people to talk to their doctor before stopping or making any changes to their anticoagulant medicines.

30 Jul 2013

Bristol-Myers Squibb, Pfizer announce FDA acceptance of Eliquis sNDA for review

Bristol-Myers Squibb Company and Pfizer Inc. today announced that the U.S. Food and Drug Administration has accepted for review a Supplemental New Drug Application for Eliquis (apixaban), for the prophylaxis of deep vein thrombosis, which may lead to pulmonary embolism, in adult patients who have undergone hip or knee replacement surgery.

11 Jul 2013

CorMedix's Neutrolin catheter lock solution receives CE Mark approval

CorMedix Inc. today announced that it has received CE Mark approval for Neutrolin, a catheter lock solution, for patients with central venous catheters on hemodialysis secondary to advanced chronic kidney disease.

6 Jul 2013

Expertly written, practical handbook of pediatric thrombosis and hemostasis

An expertly written, practical handbook for the clinical assessment and management of children with inherited or acquired bleeding and clotting disorders

4 Jul 2013

Anticoagulant News and Research

Regado Biosciences employs over-allotment option to purchase additional shares of common stock

Hokusai-VTE findings provide fresh insight into patients with pulmonary embolism

NPS MedicineWise reiterates safety messages around newer oral anticoagulants

Mass screening programme of 75-76 year olds to identify undiagnosed AF

Use of anticoagulant does not reduce ischemic events among patients undergoing PCI

Research: General practitioners undertreat women with atrial fibrillation

Personalised management: The only way to close mortality gap for AF patients

Vanderbilt adds genetic screening for drug tacrolimus to PREDICT program

Scientists grow cells that line blood vessels from human iPSCs

Boehringer signs agreement with Brigham to conduct long-term study program on oral anticoagulants

FDA grants Orphan Drug Designation to Alnylam ALN-AT3 for treatment of hemophilia B

"Risk calculator" enables doctors to estimate risk of venous thrombosis

AliveCor Heart Monitor for iPhone can detect heart rhythm problems, prevent strokes

Prothrombin complex concentrates more effective at reversing hemorrhage caused by warfarin

August edition of NPS RADAR includes reviews for new medicines listed on PBS

Viewpoints: GOP's shutdown vow; Peter Orszag defends rationale behind Medicare payment board

NPS MedicineWise finds little or no clinical benefit in switching to rivaroxaban for stroke prevention

Bristol-Myers Squibb, Pfizer announce FDA acceptance of Eliquis sNDA for review

CorMedix's Neutrolin catheter lock solution receives CE Mark approval

Expertly written, practical handbook of pediatric thrombosis and hemostasis

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News